ranolazine

Brief Communication

Ranolazine in Chronic Total Occlusion Percutaneous Coronary Intervention

04/30/2024

Michaella Alexandrou, MD¹; Deniz Mutlu, MD¹; Athanasios Rempakos, MD¹; Ahmed Al Ogaili, MD¹; James W. Choi, MD^2,3; Paul Poommipanit, MD⁴; Khaldoon Alaswad, MD⁵; Mir Babar Basir, DO⁵; Rhian Davies, DO, MS⁶; Farouc A. Jaffer, MD, PhD⁷; Phil Dattilo, MD⁸; Lorenzo Azzalini, MD, PhD, MSc⁹; Nazif Aygul, MD¹⁰; Niranjan Reddy, MD¹¹; Brian K. Jefferson, MD¹²; Sevket Gorgulu, MD¹³; Jaikirshan J. Khatri, MD¹⁴; Laura D. Young, MD¹⁴; Oleg Krestyaninov MD¹⁵; Dmitrii Khelimskii MD¹⁵; Jarrod Frizzell, MD¹⁶; Basem Elbarouni, MD¹⁷; Bavana V. Rangan, BDS, MPH¹; Olga C. Mastrodemos, BA¹; M. Nicholas Burke, MD¹; Yader Sandoval, MD¹; Emmanouil S. Brilakis, MD, PhD¹

Michaella Alexandrou, MD1; Deniz Mutl...

The authors analyzed a large, multicenter chronic total occlusion (CTO) percutaneous coronary intervention (PCI) registry to determine the baseline clinical and angiographic characteristics and procedural outcomes of patients undergoing CTO...

The authors analyzed a large,...

04/30/2024

Journal of Invasive Cardiology